# Remission and Joint Damage Progression in Early Rheumatoid Arthritis

> **NCT00122382** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1052 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Abatacept
- **DRUG:** placebo
- **DRUG:** methotrexate

## Key facts

- **NCT ID:** NCT00122382
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2008-02
- **Final completion:** 2009-02
- **Target enrollment:** 1052 (ACTUAL)
- **Last updated:** 2010-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00122382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00122382, "Remission and Joint Damage Progression in Early Rheumatoid Arthritis". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00122382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*